Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Licenses Kreutzer-Limmer RNAi IP to GeneDesign

NEW YORK (GenomeWeb News) - Alnylam Pharmaceuticals said today it has granted a non-exclusive license to the Kreutzer-Limmer family of RNAi patents to GeneDesign, a Japanese supplier of siRNAs.
 
Under the terms of the agreement, GeneDesign has gained the right to provide RNAi research products and services under the patent family, which covers siRNAs and their use in mediating RNAi in mammalian cells.
 
GeneDesign's president, Kazuhiko Yuyama, said the license to this patent estate "allows us to augment our RNAi products, thereby strengthening our position in the life sciences marketplace in Asia."
 
Alnylam's VP of business development, Jason Rhodes, said it now has licensed the IP to three research products suppliers in Asia, and 15 suppliers worldwide.
 
“We believe that the vast majority of industrial sales of siRNAs for research purposes globally are currently being made under access to Alnylam's intellectual property," Rhodes said.
 
Financial terms of the agreement were not released.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.